

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

OVCAR-5

RRID:CVCL_1628

Type: Cell Line

Proper Citation

RRID:CVCL_1628

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1628

Proper Citation: RRID:CVCL_1628

Description: Cell line OVCAR-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:1348364](#), [PMID:2041050](#), [PMID:2307530](#), [PMID:3335022](#), [PMID:3930572](#), [PMID:6385258](#), [PMID:7718330](#), [PMID:9041185](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12417041](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:19926575](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:22068913](#), [PMID:22328975](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24434149](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27353327](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:35681748](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Possibly misclassified. Originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin (PubMed=27353327)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-5

Synonyms: OVCAR 5, NIH:OVCAR-5, OVCAR.5, OVCAR5, OvcAR5, OVCA5

Cross References: BTO:BTO_0001870, CLO:CLO_0008280, EFO:EFO_0005443, CLDB:cl3781, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:982, BioSample:SAMN03472888, BioSample:SAMN10989589, cancercellines:CVCL_1628, Cell_Model_Passport:SIDM00091, ChEMBL-Cells:ChEMBL3307565, ChEMBL-Targets:ChEMBL614214, CLS:305616, Cosmic:875861, Cosmic:897435, Cosmic:905969, Cosmic:974297, Cosmic:1044241, Cosmic:1092625, Cosmic:1093554, Cosmic:1102824, Cosmic:1175885, Cosmic:1305314, Cosmic:1312356, Cosmic:1436035, Cosmic:1523763, Cosmic:1707573, Cosmic:1709255, Cosmic:1995605, Cosmic:1998467, Cosmic:2186583, Cosmic-CLP:905969, DepMap:ACH-001151, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905969, GEO:GSM2126, GEO:GSM50221, GEO:GSM50285, GEO:GSM185139, GEO:GSM185140, GEO:GSM659394, GEO:GSM711709, GEO:GSM743476, GEO:GSM743493, GEO:GSM743512, GEO:GSM743513, GEO:GSM743514, GEO:GSM743515, GEO:GSM743516, GEO:GSM743517, GEO:GSM743518, GEO:GSM743519, GEO:GSM743520, GEO:GSM743521, GEO:GSM743522, GEO:GSM743523, GEO:GSM743524, GEO:GSM750830, GEO:GSM784573, GEO:GSM799365, GEO:GSM799428, GEO:GSM844671, GEO:GSM847108, GEO:GSM851936, GEO:GSM1153437, GEO:GSM1178525, GEO:GSM1178526, GEO:GSM1181280, GEO:GSM1181287, GEO:GSM1340587, GEO:GSM1374802, GEO:GSM1670319, GEO:GSM2124678, GEO:GSM2474993, Millipore:SCC259, NCI-DTP:OVCAR-5, PharmacDB:OVCAR5_1219_2019, PRIDE:PXD003539, PRIDE:PXD003668, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1628, PubChem_Cell_line:CVCL_1628, SKY/M-FISH/CGH:2818, Wikidata:Q54937011

ID: CVCL_1628

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235526+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-5.

Warning: Problematic cell line: Possibly misclassified. Originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin (PubMed=27353327).

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Possibly misclassified. Originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin (PubMed=27353327)..

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 213 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. *Cancer research*, 86(4), 1073.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Shao H, et al. (2026) KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. *Science advances*, 12(8), eaea2511.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Bayraktar E, et al. (2025) Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. *Cell reports. Medicine*, 6(9), 102329.

Coussens NP, et al. (2025) Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. *SLAS discovery : advancing life sciences R & D*, 33, 100230.

Delafiori J, et al. (2025) HT SpaceM: A high-throughput and reproducible method for small-molecule single-cell metabolomics. *Cell*.

Zhang S, et al. (2025) Vertical inhibition of p110 α /AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. *Molecular oncology*, 19(4), 1132.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Poirier B, et al. (2024) R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases. *British journal of pharmacology*.

Bischof K, et al. (2024) Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. *Molecular oncology*.

Wang CW, et al. (2024) A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing. *Cancer research communications*, 4(1), 253.

Shanley M, et al. (2024) Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. *Cancer cell*, 42(8), 1450.

Chai H, et al. (2023) Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development. *BMC cancer*, 23(1), 96.

Bajwa P, et al. (2023) Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. *JCI insight*, 8(6).

Arentz G, et al. (2023) Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer. *Cancers*, 15(7).

Yin J, et al. (2023) Video-rate mid-infrared photothermal imaging by single-pulse photothermal detection per pixel. *Science advances*, 9(24), eadg8814.

Minazzato G, et al. (2023) A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase. *Molecules (Basel, Switzerland)*, 28(3).

Koc ZC, et al. (2023) Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer. *Frontiers in oncology*, 13, 1129352.

Golubovskaya V, et al. (2023) mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. *Cancers*, 15(10).